News Conference News AHA 2024 Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360 Michael O'Riordan November 18, 2024
News Daily News Rosuvastatin Bests Atorvastatin for Reducing CVD Risk: Registry Data Michael O'Riordan November 07, 2024
Presentation TCT 2024 LDL Lowering in ACS- Go Big, Go Early, Then Go Home Presenter: Marc Bonaca October 29, 2024
Presentation TCT 2024 Changes in Plaque Volume and Plaque Composition After 12 Weeks of Extensive LDL-C Reduction With PCSK9 Inhibitors in ACS Patients With Multivessel Disease Presenter: Jonathan Los October 27, 2024
News Daily News Lp(a) Levels, Still Mostly Genetic, Sometimes Vary Over a Lifetime Michael O'Riordan October 14, 2024
News Daily News High Levels of Metals, Particularly Cadmium, Linked to Subclinical CVD Michael O'Riordan September 23, 2024
News Daily News Low Adherence to Secondary Prevention Recommendations Worldwide: INTERASPIRE Yael L. Maxwell September 23, 2024
News Conference News ESC 2024 Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events Michael O'Riordan September 01, 2024
News Conference News SCCT 2024 Should Coronary Calcium Always Be Noted on Noncardiac CT Reports? Todd Neale July 24, 2024
News Daily News Think You Need a Statin? AHA’s Risk Calculator May Disagree Michael O'Riordan June 28, 2024
News Daily News Excess ApoB Linked to Increased MI, ASCVD Risk in Adults Michael O'Riordan June 04, 2024
News Two siRNA Therapeutics Safely Lower Triglycerides in Mixed Hyperlipidemia Michael O'Riordan May 30, 2024
News Daily News Statins Effective For Primary Prevention in Old and Very Old Michael O'Riordan May 29, 2024
News Daily News Atherosclerosis Progression May Share Traits With Tumor Growth Caitlin E. Cox May 08, 2024
News Daily News Very Elderly Benefit From High-Intensity Lipid-Lowering After Acute MI Michael O'Riordan May 02, 2024
News Daily News Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups Michael O'Riordan April 17, 2024
News Conference News ACC 2024 Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing Michael O'Riordan April 12, 2024